Logo

PharmaShots Weekly Snapshots (September 12 - 16, 2022)

Share this
PharmaShots Weekly Snapshots (September 12 - 16, 2022)

PharmaShots Weekly Snapshots (September 12 - 16, 2022)

Enzolytics Collaborated with Abveris to Discover Monoclonal Antibodies Against Multiple Viral Infectious Diseases

Published: Sept 16, 2022 | Tags: Enzolytics, Abveris, Monoclonal Antibodies, Multiple Viral Infectious Diseases, Biotech

Agios’ Pyrukynd (mitapivat) Receives EMA's CHMP Positive Opinion Recommending the Marketing Authorization for the Treatment of PK Deficiency

Published: Sept 16, 2022 | Tags: Agios, Pyrukynd, mitapivat, PK Deficiency, Regulatory, EMA, CHMP, Positive Opinion, Marketing Authorization

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receive EMA's CHMP Positive Opinion for the Prevention of RSV Lower Respiratory Tract Disease

Published: Sept 16, 2022 | Tags: AstraZeneca, Sanofi, Beyfortus, nirsevimab, RSV Lower Respiratory Tract Disease , Regulatory, EMA, CHMP, Positive Opinion

Sanofi and Regeneron Published P-III Trial Results of Dupixent (dupilumab) for Atopic Dermatitis in The Lancet

Published: Sept 16, 2022 | Tags: Sanofi, Regeneron, Dupixent, dupilumab, Atopic Dermatitis, Clinical Trial, P-III Trial

Gilead’s Veklury (remdesivir) Receives WHO’s Recommendation for the Treatment of COVID-19

Published: Sept 16, 2022 | Tags: Gilead, Veklury, remdesivir, COVID-19, Regulatory, WHO, Recommendation

NeuroBo Entered into a Conditional Exclusive License Agreement with Dong-A to Develop and Commercialize DA-1241 and DA-1726

Published: Sept 16, 2022 | Tags: NeuroBo, Dong-A, DA-1241, DA-1726, nonalcoholic steatohepatitis, obesity, type 2 diabetes, Pharma

Ascletis Pharma Reports the Completion of Patient Enrollment of ASC22 (envafolimab) + Chidamide in Clinical Study for HIV Infection

Published: Sept 15, 2022 | Tags: Ascletis Pharma, ASC22, envafolimab, Chidamide, HIV Infection, Clinical Trial

Pfizer Reports P-III Trial Results of Pentavalent Meningococcal Vaccine (MenABCWY) for Invasive Meningococcal Disease

Published: Sept 15, 2022 | Tags: Pfizer, Pentavalent Meningococcal Vaccine, MenABCWY, Invasive Meningococcal Disease, Clinical Trial, P-III Trial

Qurient Entered into a Clinical Collaboration Agreement with MSD to Evaluate Q901 + Keytruda (pembrolizumab) for Advanced Solid Tumors

Published: Sept 15, 2022 | Tags: Qurient, MSD, Q901, Keytruda, pembrolizumab, Advanced Solid Tumors, Pharma

Mallinckrodt’s Terlivaz (terlipressin) Receives the US FDA’s Approval for the Treatment of Hepatorenal Syndrome

Published: Sept 15, 2022 | Tags: Mallinckrodt, Terlivaz, terlipressin, Hepatorenal Syndrome, Regulatory, US, FDA, Approval

Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rheumatology

Published: Sept 15, 2022 | Tags: Horizon, Krystexxa, pegloticase, Uncontrolled Gout, Clinical Trial, P-IV (MIRROR) Trial, Arthritis & Rheumatology

Neuron23 Collaborated with QIAGEN to Develop CDx for LRRK2 inhibitor to Treat Parkinson's Disease

Published: Sept 15, 2022 | Tags: Neuron23, QIAGEN, CDx, LRRK2 inhibitor, Parkinson's Disease, Pharma, US, FDA, PMA

Valeo Pharma Enters into a Commercial Services Agreement with Veru for Sabizabulin to Treat COVID-19 in Canada

Published: Sept 14, 2022 | Tags: Valeo Pharma, Veru, Sabizabulin, COVID-19, Canada, Commercial Services Agreement, Pharma

Coave Collaborated with Institute of Neurodegenerative Diseases to Develop Gene Therapy for Neurodegenerative Disorders

Published: Sept 14, 2022 | Tags: Coave, Institute of Neurodegenerative Diseases, Gene Therapy, Biotech, Neurodegenerative Disorders

MD Anderson Collaborated with Radiopharm Theranostics to Launch Joint Venture for Novel Radiopharmaceuticals Therapies

Published: Sept 14, 2022 | Tags: MD Anderson, Radiopharm Theranostics, Joint Venture, Radiopharmaceuticals Therapies, Cancer, Pharma

Otsuka and Lundbeck Report the US FDA Acceptance of NDA for Aripiprazole to Treat Schizophrenia and Bipolar I Disorder

Published: Sept 14, 2022 | Tags: Otsuka, Lundbeck, Aripiprazole, Schizophrenia, Bipolar I Disorder, Regulatory, US, FDA, NDA

Merck’s Keytruda (pembrolizumab) Receives the Health Canada Approval as Adjuvant Treatment for Stage IIB or IIC Melanoma

Published: Sept 14, 2022 | Tags: Merck, Keytruda, pembrolizumab, Stage IIB or IIC Melanoma, Regulatory, Health Canada, Approval

Nacuity Entered into an Exclusive License Agreement with Arctic to Develop and Commercialize NPI-001 in Iceland

Published: Sept 14, 2022 | Tags: Nacuity, Arctic. NPI-001, Hereditary Cystatin C Amyloid Angiopathy, Pharma, Iceland

METiS Entered into a License Agreement with Voronoi to Develop and Commercialize Pan-RAF Inhibitor Program

Published: Sept 13, 2022 | Tags: METiS, Voronoi, Pan-RAF Inhibitor Program, Class II & III BRAF mutant cancer, CNS metastasis, Pharma, License Agreement

CStone Reports NMPA Acceptance of sNDA and Granted Priority Review for Sugemalimab to treat Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma

Published: Sept 13, 2022 | Tags: CStone, Sugemalimab, Extranodal Natural Killer, T-Cell Lymphoma, regulatory, NMPA, sNDA, Priority Review 

Novo Nordisk Collaborated with Microsoft to Advance Drug Discovery and Development Using AI

Published: Sept 13, 2022 | Tags: Novo Nordisk, Microsoft, atherosclerosis, AI, Drug Discovery, Pharma

Pfizer and BioNTech Receive EMA's CHMP Positive Opinion Recommending Conditional Marketing Authorization for Omicron BA.4/BA.5 Bivalent Booster Vaccine

Published: Sept 13, 2022 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5 Bivalent Booster Vaccine, Regulatory, EMA, CHMP, Conditional Marketing Authorization

Astellas, Seagen and Merck Report P-Ib/II (EV-103/KEYNOTE-869) Cohort K Trial Results of Padcev (enfortumab vedotin-ejfv) as 1L Treatment of Advanced Urothelial Cancer

Published: Sept 13, 2022 | Tags: Astellas, Seagen, Merck, Padcev, enfortumab vedotin-ejfv, Advanced Urothelial Cancer, Clinical Trial, P-Ib/II EV-103/KEYNOTE-869, Cohort K Trial

AmerisourceBergen to Acquire PharmaLex for ~$1.30B

Published: Sept 13, 2022 | Tags: AmerisourceBergen, PharmaLex, Acquire, ~$1.30B, M&A

AstraZeneca Reports P-III (POSEIDON) Trial Results of Imfinzi (durvalumab) for Metastatic Non-Small Cell Lung Cancer

Published: Sept 12, 2022 | Tags: AstraZeneca, Imfinzi, durvalumab, Metastatic Non-Small Cell Lung Cancer, Clinical Trial, P-III POSEIDON Trial

Ra Medical Systems & Catheter Precision Entered into a Definitive Merger Agreement to Treat Cardiac Arrhythmias

Published: Sept 12, 2022 | Tags: Ra Medical Systems, Catheter Precision, VIVO, Amigo, Cardiac Arrhythmias, M&A, Merger Agreement

Cellusion Entered into an Exclusive License Agreement with Celregen for CLS001 in the Greater China

Published: Sept 12, 2022 | Tags: Cellusion, Celregen, CLS001, bullous keratopathy, Pharma, Greater China

BMS’ Sotyktu (deucravacitinib) Receives the US FDA’s Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

Published: Sept 12, 2022 | Tags: BMS, Sotyktu, deucravacitinib, Plaque Psoriasis, Regulatory, US, FDA, Approval

Amgen Presents P-III (CodeBreaK 200) Trial Results of Lumakras/Lumykras (sotorasib) for Non-Small Cell Lung Cancer at ESMO 2022

Published: Sept 12, 2022 | Tags: Amgen, Lumakras, Lumykras, sotorasib, Non-Small Cell Lung Cancer, Clinical Trial, P-III, CodeBreaK 200 Trial

AstraZeneca and Merck Present P-III (PAOLA-1) & (SOLO-1) Trial Results of Lynparza (olaparib) as 1L Treatment of Advanced Ovarian Cancer at ESMO

Published: Sept 12, 2022 | Tags: AstraZeneca, Merck, Lynparza, Olaparib, Advanced Ovarian Cancer, P-III, PAOLA-1, SOLO-1, Trial

Related Post: PharmaShots Weekly Snapshots (September 05 - 09, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions